Arovella licenses novel CAR-iNKT cell armouring technology
Filed with ASX · · 29 pages · English and French
• Arovella has entered into a global, exclusive license with University of North Carolina Lineberger Comprehensive Cancer Center to incorporate a novel armouring cytokine technology (IL-12-TM) for its CAR-iNKT cell platform • Arovella is the only company globally developing IL-12-TM armoured CAR-iNKT cells • This armouring cytokine technology: o results in a ten-fold increase in circulating CAR-iN
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Arovella receives R&D tax credit of $1.94 million
- Arovella licenses novel solid tumour targeting technology
- Reinstatement to Quotation
- Suspension from Quotation
- Response to ASX Price Query
Later from Arovella Therapeutics
- Appendix 4D and Half Year Report
- Pause in Trading
- Arovella Completes $12.5M Placement - Funded to Phase 1 Data
- Arovella completes manufacturing scale-up
- Zolpimist Update
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics